Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Consensus Price Target from Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has been assigned an average rating of “Buy” from the five ratings firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.00.

Several research analysts have issued reports on TENX shares. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Guggenheim assumed coverage on Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price on the stock. Leerink Partners initiated coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price for the company. StockNews.com began coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating for the company. Finally, William Blair assumed coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock.

Tenax Therapeutics Stock Up 0.9 %

Shares of TENX opened at $5.61 on Friday. The firm’s 50 day moving average is $4.95 and its 200-day moving average is $4.01. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $27.33.

Institutional Trading of Tenax Therapeutics

A number of hedge funds have recently modified their holdings of the business. Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics during the third quarter valued at $101,000. Vestal Point Capital LP purchased a new position in Tenax Therapeutics during the 3rd quarter valued at about $288,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics in the 3rd quarter valued at about $173,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.